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Worldwide, measures are being implemented to eradicate hepatitis B (HBV) and C (HCV)
viruses, which can be transmitted from the mother during childbirth. This study aims to
determine the prevalence of HBV and HCV in pregnant women in Spain, focusing on coun-
try of origin, epidemiological factors and risk of vertical transmission (VT).
Methodology
Multicentre open-cohort study performed during 2015. HBV prevalence was determined in
21870 pregnant women and HCV prevalence in 7659 pregnant women. Epidemiological
and risk factors for VT were analysed in positive women and differences between HBV and
HCV cases were studied.
Results
HBV prevalence was 0.42% (91/21870) and HCV prevalence was 0.26% (20/7659). Of the
women with HBV, 65.7% (44/67) were migrants. The HBV transmission route to the mother
was unknown in 40.3% of cases (27/67) and VT in 31.3% (21/67). Among risk factors for
VT, 67.7% (42/62) of the women had viraemia and 14.5% (9/62) tested HBeAg-positive. All
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of the neonates born to HBV-positive mothers received immunoprophylaxis, and none con-
tracted infection by VT. In 80% (16/20) of the women with HCV, the transmission route was
parenteral, and nine were intravenous drug users. Viraemia was present in 40% (8/20) of
the women and 10% (2/20) were HIV-coinfected. No children were infected. Women with
HCV were less likely than women with HBV to breastfeed their child (65% vs. 86%).
Conclusions
The prevalences obtained in our study of pregnant women are lower than those previously
documented for the general population. Among the women with HBV, the majority were
migrants and had a maternal family history of infection, while among those with HCV, the
most common factor was intravenous drug use. Despite the risk factors observed for VT,
none of the children were infected. Proper immunoprophylaxis is essential to prevent VT in
children born to HBV-positive women.
Introduction
According to the World Health Organization (WHO) [1], chronic infection by hepatitis B
virus (HBV) affects 257 million people. It is particularly prevalent in sub-Saharan Africa and
in East Asia, affecting 5–10% of all adults, while in North America, less than 1% are infected.
The estimated prevalence is less than 5% in eastern Europe, 1.5% in northern Europe, 2% in
southern Europe and 1% in western Europe. However, these values are probably underesti-
mates because, among other reasons, the data are obtained from blood donors [2]. Moreover,
the situation in Europe may be adversely affected by changing patterns of migration [3,4].
According to a systematic review conducted by the European Centre for Disease Prevention
and Control (ECDC) [5] based on articles published from 2005 to 2015, the prevalence in
Spain was around 0.8% (0.6–1.1) and according to the latest report available [3] it was 0.66%
(0.34–0.97).
The WHO has reported that 71 million people are infected with hepatitis C virus (HCV) [1]
and that the most severely affected regions are Europe and the Eastern Mediterranean (2.3%).
In Europe, the prevalence of HCV antibodies (anti-HCV) is estimated at 1.1% (95%CI 0.9–1.4)
[5]. In Spain, the prevalence of antibodies is 1.7% and that of viraemia (HCV RNA positive) is
1.2% [6]. In the Ethon Cohort [7], the prevalence of anti-HCV positive (anti-HCV+ve) was
1.23% and only 0.32% had viraemia. However, this prevalence might be affected by changes in
patterns of migration in Europe, especially in Spain [8].
In Spain, the prevalence of HBV infection (surface antigen positive) in pregnant women
ranges from 0.1% to 4.4% [5,9,10]. The vertical transmission (VT) of HBV continues to be one
of the main routes of infection worldwide [11], especially in areas where it is endemic [12].
High viral load (VL), which mainly affects HBeAg-positive (HBeAg+ve) women, is the most
important risk factor, although women who are HBeAg-negative (HBeAg-ve) and who present
high VL are also at risk of transmission [13]. In this population, 90% chronicity of infected
newborns has been reported [14].
The prevalence of anti-HCV in pregnant women in Spain is estimated to be 0.5–1.4%
[9,15,16], and the prevalence of viraemia 42–72%. The rate of VT among women with HCV is
low, 1–8% in non-coinfected mothers and around 20% in those coinfected with HIV. How-
ever, 90% of infected children acquire the virus by VT. The factors related to the VT of HCV
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are VL and HIV coinfection [17–19]. No other factors related to childbirth, epidemiology or
breastfeeding have been associated with VT.
Screening for HBV in pregnancy is routinely recommended, as immunoprophylaxis against
VT is feasible [12,20]. According to 2015 data, generalised immunoprophylaxis at birth has
reduced the proportion of chronically-infected children aged under five years from 4.7% to
1.3% [1]. Nevertheless, up to 10% of newborns whose mothers present high VL become
infected [14,21]. Accordingly, it is recommended that in HBV+ve women, VL should be
assessed at 24 weeks of pregnancy and antiviral treatment administered if the VL is high. On
the other hand, the determination of HCV in pregnancy is only recommended for at-risk pop-
ulations such as intravenous drug users, women with high-risk sexual practices, women with
HIV coinfection and women born in countries with high endemicity for HCV. In conse-
quence, the prevalence reported in the literature may not correspond to reality. Prophylactic
and therapeutic measures to eradicate HBV and HCV are currently being implemented. Chil-
dren infected by VT should be included in this programme, but screening during pregnancy
for HCV is not yet universal, and therefore some children who acquire the virus through VT
will remain undiagnosed.
In view of these considerations, the main aim of this study is to determine the prevalence of
HBV and HCV in pregnant women in Spain, taking into account their country of origin, epi-
demiological factors and the risk of VT.
Material and method
Patients
To determine the prevalence of HBV and HCV among a population of pregnant women, a
multicentre prospective open-label cohort study was carried out from January to December
2015. The following hospitals took part: Hospital Universitario 12 de Octubre Madrid
(HU12O), Hospital Universitario La Paz Madrid (HULP), Hospital Universitario San Cecilio
Granada (HUSC), Hospital Universitario Virgen de las Nieves Granada (HUVN), Hospital
Universitario Central de Asturias Oviedo (HUCA), Hospital Universitario Torrecárdenas
Almerı́a (HUT), Hospital Universitario Virgen del Rocı́o Sevilla (HUVR) and Hospital Uni-
versitario Virgen de la Victoria Málaga (HUVV).
The population analysed in the HBV prevalence study consisted of 21870 pregnant women,
whose data were provided by the researchers at each hospital, from an anonymised database
managed by its Microbiology Service, which compiles and manages these data as usual clinical
practice in pregnancy. After the delivery, the mothers found to be HBV-positive (HBV+ve)
were invited to participate in the study, by completing the epidemiological survey, stating their
country of origin and providing details of the delivery. In every case, the mother’s informed
consent was obtained. In addition, the donation of blood samples from each mother and child
was requested, together with consent for medical follow-up of the neonate for 18 months. Fig
1 shows the flow chart for the recruitment of these participants.
In Spain, the determination of HCV does not form part of usual clinical practice, and so
informed consent in this respect was requested and obtained in every case included in this
study. Accordingly, tests for HCV were performed on 7659 women in week 12 of pregnancy,
during the scheduled hospital visit for the detection of chromosomopathies. After the delivery,
the mothers found to be HCV positive (HCV+ve) were invited to participate in the study, by
completing the epidemiological survey, stating their country of origin and providing details of
the delivery. In every case, informed consent in this respect was obtained. In addition, the
donation of blood samples from the mother and child was requested, together with consent for
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medical follow-up of the neonate for 18 months. Fig 1 shows the flow chart for the recruitment
of these participants.
The inclusion criteria were HBV surface antigen positive (HBsAg+ve) or anti-HCV+ve sta-
tus confirmed by enzyme-linked immunosorbent assay (ELISA) and the provision of informed
consent.
Epidemiological study
The study variables were participant’s age, country of origin and risk factors for infection. The
risk factors considered were transfusion, intravenous drug abuse (IVDA), tattoos, piercing,
Fig 1. Flow chart for selection of participants. This figure shows the flow chart of pregnant women recruitment for prevalence, epidemiological and risk
factors for vertical transmission studies.
https://doi.org/10.1371/journal.pone.0233528.g001
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surgery, dental treatment, infected partner, high-risk sexual practices, history of infection in
the participant’s mother or siblings and HIV coinfection, categorised as yes, no or unknown.
The survey also asked whether the woman knew about the infection prior to her pregnancy.
The route of transmission of infection was categorised as vertical, parenteral, sexual or
unknown.
Risk factors for vertical transmission
Antigen E (HBeAg) and antibody E (anti-HBe) were analysed for HBV, and VL was analysed
for HBV and/or HCV.
The HBV+ve women were classified according to the EASL Clinical Practice Guidelines
[22] as HBeAg-positive chronic infection (HBeAg+ve and DNA >107 IU/mL), HBeAg-posi-
tive chronic hepatitis (HBeAg+ve and DNA 104−107 IU/mL), HBeAg-negative chronic infec-
tion (HBeAg-ve and DNA <2000 IU/mL) and HBeAg-negative chronic hepatitis (HBeAg-ve
and DNA>2000 IU/mL).
Other information compiled for the study included data on the pregnancy and delivery,
including in vitro fertilisation, antiviral treatment for HBV during pregnancy, type of delivery,
gestational age, time elapsed since the breaking of the waters, weight, Apgar score of the neo-
nate at birth and the type of lactation.
The study protocol is the same as has been described in previous studies by this research
group (17–19).
Analysis of the differences between HBV and HCV
The dependent variable was HBV+ve versus HCV+ve. The remaining variables were assumed
to be independent.
Virologic assays
The serological determination of HBsAg, anti-HCV and anti-HIV was carried out by commer-
cial ELISA, which is routinely used in the laboratories of each of the participating hospitals.
The VL of HBV and/or HCV was determined by COBAS TaqMan (cut-off <12 IU/mL,
<15 IU/mL. Roche Diagnostics, respectively), distinguishing between not detected, below cut-
off but not quantifiable and greater than cut-off and quantifiable. In the HBV+ve women,
HBeAg and anti-HBe were also determined.
Statistical analysis
In our statistical analysis, the quantitative variables are described by the mean and the standard
deviation, or in cases of non-normal distribution, by the median and the interquartile range.
The qualitative variables are presented as absolute and relative frequencies. The corresponding
prevalences and 95% confidence intervals were also calculated. The inter-group differences
were determined by bivariate analysis, using Pearson’s chi-square test or Fisher’s exact test for
the qualitative variables and Student’s t test or the Mann-Whitney U test for the continuous
ones. The normality of the data distribution was examined by the Kolmogorov-Smirnov test.
A p-value <0.05 was considered significant. All data analyses were performed using IBM SPSS
19 statistical software.
Ethical considerations
This study was carried out in accordance with the ethical guidelines of the Declaration of Hel-
sinki of 1975, revised in 2013. All participants gave written and verbal informed consent. The
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study protocol was firstly approved by Comité Ético de Investigación Provincial de Granada
(Ethics Committee of the Principal Investigator’s hospital) and later by the Ethics Committee
at each participating hospital. The relevant provisions of Spanish data protection legislation
were respected in all phases of the study.
Results
Prevalence of HBV and HCV in pregnancy
The prospective cohort for the HBV study consisted of 21870 pregnant women, of whom 91
were HBsAg+ve, with a prevalence of 0.42% (95% CI 0.33–0.50). Table 1 shows the distribu-
tion among the participating hospitals. The cohort for the HCV study contained 7659 women,
of whom 20 were anti-HCV+ve, with a prevalence of 0.26% (95% CI 0.15–0.38). The preva-
lence of HBV differed significantly among the hospitals (p = 0.013), lowest at HUCA and high-
est at HULP, HUT and HUVR. On the other hand, the inter-hospital differences for anti-HCV
prevalence were not significant (p = 0.52).
Epidemiology and risk factors for vertical transmission in HBV-positive
women
Of the 67 women included in the study, 31 (46.3%) were aware of the infection prior to preg-
nancy. None were coinfected with HCV, and there was one case (1.5%) of coinfection with
HIV. By country of birth, 22 (32.8%) were Spanish, followed in frequency by those from China
and Eastern Europe (Fig 2). The risk factors for infection in these pregnant women are shown
Table 1. Seroprevalence of HBV and HCV among pregnant women at each hospital.
HBV Positive cases Women (n) Prevalence (%) 95%CI
HU12Oa 18 4224 0.42 0.22–0.62
HULPb 17 2901 0.59 0.31–0.86
HUSCc –HUVNd 9 2262 0.39 0.14–0.66
HUCAe 1 2362 0.04 0.01–0.12
HUTf 13 2037 0.64 0.29–0.98
HUVRg 29 5903 0.49 0.32–0.67
HUVVh 4 2181 0.18 0.004–0.362
Total 91 21870 0.42 0.33–0.50
HCV Positive cases Women (n) Prevalence (%) 95%CI
HULPb 7 2901 0.24 0.06–0.42
HUSCc –HUVNd 2 903 0.22 0.01–0.53
HUCAe 5 1713 0.29 0.04–0.55
HUTf 3 1671 0.18 0.01–0.38
HUVVh 3 471 0.64 0.01–1.34
Total 20 7659 0.26 0.15–0.38
aHU12O: Hospital Universitario 12 de Octubre, Madrid.
bHULP: Hospital Universitario La Paz, Madrid.
cHUSC: Hospital Universitario San Cecilio, Granada.
dHUVN: Hospital Universitario Virgen de las Nieves, Granada.
eHUCA: Hospital Universitario Central de Asturias, Oviedo.
fHUT: Hospital Universitario Torrecárdenas, Almerı́a.
gHUVR: Hospital Universitario Virgen del Rocı́o, Sevilla.
hHUVV: Hospital Universitario Virgen de la Victoria, Málaga.
https://doi.org/10.1371/journal.pone.0233528.t001
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in Table 2. The route of transmission was parenteral in 14 cases (20.9%), vertical in 21 (31.3%),
sexual in 3 (4.5%) and unknown in 27 (40.3%). Of the women presenting VT, 13 (61.9%) were
of foreign origin.
Of the 62 HBsAg+ve women who provided samples, 42 (67.7%) had viraemia. Nine (14.5%)
were HBeAg+ve and one (with a twin pregnancy) had chronic infection with a VL of 2070 IU/
mL at the moment of delivery. Of the eight women who had HBeAg+ve chronic infection, six
were treated during pregnancy: three achieved undetectable VL before delivery and in the
other three the maximum VL was 1448 IU/mL. The two HBeAg+ve women who were not
treated had a VL>108 IU/mL. Two of the HBeAg+ve women were Spanish, five were Chinese,
one was from Central America and one was from sub-Saharan Africa. The ten neonates were
monitored after birth, and none became infected. Of the 53 (85.5%) women who were HBeAg-
ve, 40 had chronic infection and 13 had chronic hepatitis.
None of the pregnancies was achieved by in vitro fertilisation. The birth was spontaneous
in 47 (72.3%) cases, by caesarean section in 13 (20%) (two of which were scheduled) and by
instrumental delivery in five (7.7%). The data for the 69 neonates are summarised in Table 3.
Only one of the low-weight children had a maternal history of antiviral treatment. Of the 30
neonates in whom the VL was analysed at birth, two were HBV+ve, although later tests were
negative. All of the neonates born to HBsAg+ve women received immunoprophylaxis during
the first twelve hours of life, for an average of 3.4 ± 3 hours. The ten children born to HBeAg
Fig 2. Geographic origin of pregnant women with HBV or HCV infection. This figure shows the geographic origin of the pregnant women with HBV or HCV
infection who participated in the epidemiological study, expressed in relative frequency.
https://doi.org/10.1371/journal.pone.0233528.g002
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+ve women received immunoprophylaxis in the first three hours of life. None of the 54 chil-
dren who completed the follow-up became infected.
Epidemiology and risk factors for vertical transmission in HCV-positive
women
Thirteen women (65%) were previously aware of their HCV infection. None were coinfected
with HBV and there were two cases (10%) of coinfection with HIV. By country of origin, the
majority of women were from Spain (11 cases, 55%) and Eastern Europe (four cases, 20%) (Fig
2). The risk factors for infection are detailed in Table 2. The route of transmission was paren-
teral in 16 women (80%), of whom nine had a history of IVDA. The route of transmission was
unknown in four cases (20%).
HCV RNA was positive (HCV-RNA+ve) in eight (40%) of the 20 women, with an average
VL of 1.9x105 IU/mL (4.4x105–3.5x106 IU/mL). The distribution of genotypes was 1b (25%), 3
(25%), 4c (12.5%) and unknown (37.5%).
None of the pregnancies was achieved by in vitro fertilisation. Delivery was spontaneous in
12 cases (60%), by caesarean section in four (20%) and by instrumental delivery in four (20%).
The data for the 20 neonates are summarised in Table 3. Five children of the eight women with
viraemia completed the follow up and none became infected.
Analysis of the differences between HBV and HCV-positive pregnant
women
As can be seen in Table 2, 65.7% (44/67) of the women with HBV were foreign born, versus
only 45% (9/20) of the women with HCV. Nevertheless, the difference was not statistically sig-
nificant (p = 0.07). A similar pattern was observed for the unknown route of maternal infec-
tion, which was more frequent among the women with HBV than those with HCV (40.3% vs.
20%; p = 0.066). VT as the mechanism of infection was more frequent for the HBV+ve women
Table 2. Epidemiology of pregnant women infected with HBV or HCV.
HBV n = 67 HCV n = 20 P
Median age of the mother [P25-P75] 33 [28–37] 34 [32.2–35.7] 0.106
Aware of infection 31 (46.3%) 13 (65%) 0.128
Co-infection with HIV 1 (1.5%) 2 (10%) 0.125
Country of origin
Spain 22 (32.8%) 11 (55%) 0.070
Other 44 (65.7%) 9 (45%)
Transfusion 1 (1.5%) 3 (15%) 0.043
IVDAa 0 (0%) 9 (45%) <0.001
Tattoo 6 (9%) 2 (10%) 1
Piercing 3 (4.5%) 1 (5%) 1
Surgery 13 (19.4%) 6 (30%) 0.383
Dental treatment 4 (6%) 1 (5%) 1
Infected partner 3 (4.5%) 3 (15%) 0.143
High-risk sexual practices 3 (4.5%) 3 (15%) 0.148
Family historyb 21 (31.3%) 0 (0%) 0.001
Unknown route of infection 27 (40.3%) 4 (20%) 0.066
aIVDA: Intravenous drug abuse.
bFamily history: previous infection in the mother or siblings.
https://doi.org/10.1371/journal.pone.0233528.t002
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(31.3% vs. 0%; p = 0.001), while IVDA was more frequent in the HCV group (45% vs. 0%;
p<0.001). Previous blood transfusion was also significantly higher in the HCV group (15% vs.
1.5%; p = 0.043).
There were no statistically significant differences among the neonates for any of the vari-
ables analysed, except that a significantly lower proportion of the women with HCV breastfed
their children (65% vs. 86%; p = 0.044) (Table 3).
Discussion
In our study population, the prevalence of HBV was 0.42% (91/21870) and that of HCV was
0.26% (20/7659). The HBV+ve women were more likely to be foreign born than those with
HCV. The most frequent route of transmission of HBV was of unknown origin, while among
those of known origin, VT was most commonly observed. Regarding the risk factors for VT,
67.7% of the women presenting HBV had viraemia and 14.5% were HBeAg+ve. Immunopro-
phylaxis was administered correctly to all the neonates born to HBV+ve mothers. Among the
HCV+ve mothers, the parenteral route of transmission was most common, mainly due to
IVDA. In the HCV group, 40% had viraemia and 10% were co-infected with HIV. The HCV
+ve women were less likely than HBV+ve to breastfeed their children.
In this study, the observed prevalence of HBsAg+ve was significantly different among the
participant hospitals. The highest level was obtained for the HUT in Almeria (0.64%), a hospi-
tal that serves a large migrant population from North and sub-Saharan Africa. In contrast, the
data for anti-HCV prevalence were fairly consistent among the participant hospitals, with the
sole exception of the HUVV in Malaga, where the prevalence was higher, although in this case
the sample size was very small.
In the general population in Spain, the prevalence of HBV is 0.66% (0.34–0.97) [3], which is
higher than the prevalence we found in pregnant women. In a previous study conducted in
1986–89 [23] at the HUSC in Granada, based on a population of 4450 pregnant women, the
prevalence of HBV was 1.53% (95% CI 1.14–1.92). Thirty years later, according to our find-
ings, the prevalence in this city has fallen to 0.39%. For comparison, a 2009 study by Salleras
et al. [24], with a population of pregnant women in Catalonia, and which has been taken as a
benchmark for Spain by the ECDC [5], recorded a very low prevalence, of 0.1%.
Our findings show that 65.7% of the participants who were HBV+ve were foreign born,
with a particularly strong presence of women from China and eastern Europe, which corrobo-
rates the pattern reported previously [25,26]. In a study conducted in Madrid [26], the highest
rate of seropositivity was found among women from Romania and other Eastern European
countries (23.7%), followed by those from China (20.3%) and sub-Saharan Africa (18.6%). In
recent years, the prevalence of HBV in Spain has tended to decrease, and if the population con-
sidered excluded those of foreign origin, the prevalence would probably be even lower.
Table 3. Characteristics of the neonates born to HBV or HCV-positive mothers.
HBV n = 69 HCV n = 20 P
Prematurea 8 (11.6%) 4 (20%) 0.265
Weight (g) Mean ± standard deviation 3194.7 ± 681 2998.8 ± 582 0.248
Time elapsed since breaking of the waters (h) Mean ± standard deviation 7 ± 8 12 ± 17 0.212
Apgar score Median [P25-P75] 9 [5–10] 9 [6–10] 0.834
Breastfeeding 55 (86%) 13 (65%) 0.044
aPremature: gestational age <37 weeks.
https://doi.org/10.1371/journal.pone.0233528.t003
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In most of the cases analysed in our study, the route of transmission of HBV infection was
unknown, while the most common of the known routes was maternal family history of HBV
infection (31.3%), although some women presented several risk factors for infection. A large
majority of the women (67.7%) had viraemia and therefore were potential transmitters of
infection. 14.5% were HBeAg+ve, which increased the risk of transmission still further. How-
ever, only six of these women received antiviral treatment during their pregnancy, which
shows that not all hospitals follow clinical practice guidelines in this respect [22]. A previous
study carried out in Granada with 4169 pregnant women [25] reported that HBV was present
in 27, of whom only one (a woman of Asian origin) was HBeAg+ve.
All of the 69 neonates born to HBV+ve mothers received immunoprophylaxis during the
first twelve hours of life, and the ten children born to HBeAg+ve women received immuno-
prophylaxis in the first three hours of life. None of the 54 neonates who completed the follow
up became infected. This includes the two children of HBeAg+ve women with high VL who
were untreated, which highlights the importance of correctly administering immunoprophy-
laxis to neonates at an early stage of life.
In our study, the prevalence of HCV was 0.26%, and only 40% of these cases were
HCV-RNA+ve. On the other hand, previous studies in the general population have found a
higher prevalence, of 1.7% (0.4–2.6), with HCV-RNA+ve in 68.6% of these cases [27]. Never-
theless, research has shown that the prevalence of HCV is lower among women than in the
general population. In a study conducted in the United States [28], the prevalence in men was
1.56% versus 0.75% in women. In another study, also conducted in the USA [29], with 87924
pregnant women, the prevalence of HCV was 1.2%. In Navarre (Spain), a study of 7314 pre-
surgical patients [30] revealed a prevalence of 0.94%, with higher values for men than for
women (1.25% vs. 0.62%, p = 0.0049). Finally, a study carried out in 1993–95 with 3003 preg-
nant women at the HUSC in Granada [19] reported that only 19 were HCV+ve (0.63%) while
14 (74%) presented viraemia. Thus, the value of 0.26% obtained in the present study is much
lower than these previous findings.
Among our study population, 55% of the women with HCV were Spanish, followed in fre-
quency by those from Eastern Europe (20%), which is in line with previous findings [31].
According to earlier research [27], 80% of the cases recorded worldwide with positive viraemia
are located in 31 countries, one of which is Spain, but over half of the infections correspond to
just six countries: China, Pakistan, Nigeria, Egypt, India and Russia. Parenteral transmission is
the most common route of infection, and most cases involve a history of IVDA, although in
20% of cases the origin of the infection is not known. This knowledge gap could justify the
introduction of HCV screening in pregnancy. Similar findings have been reported in other
studies [29,32,33]. Infection is significantly more frequent in people aged under 30 years, those
who are of European descent, especially those from Eastern Europe, and those with a history
of IVDA. The most frequent genotypes recorded in our study were 1b and 3, followed by 4,
which is consistent with previous research findings [33]. Two women (10%) had co-infection
by HIV, which increases the probability of HCV being transmitted to the child [17].
Among the children of women with HCV infection, 20% were premature, a value that is
higher than in the general population. Moreover, only 65% initiated breastfeeding, which is
well below the figure for children of HBV+ve mothers (86%) and the general population.
These findings may be more influenced by the history of IVDA than by the HCV per se [34].
This may also be the reason why not all the children of mothers with viraemia completed the
follow up.
Among the specific characteristics differentiating the HBV+ve women were the predomi-
nance of infection by VT and the larger proportion who breastfed their children. In addition,
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more were foreign born, compared to the women with HCV. In the HCV group, the main dis-
tinguishing features observed were blood transfusion and a history of IVDA.
The main limitation of this study concerned the determination of HCV in the pregnant
women, since screening for this condition is not universal in Spain during pregnancy, and
therefore signed informed consent was required. For this reason, the sample size for our analy-
sis of HCV prevalence was lower than that for HBV. Furthermore, some of the Spanish hospi-
tals that were invited declined to participate. Another limitation concerned the follow-up of
the children of seropositive mothers; many of these children were adopted after birth and so
their place of residence changed.
In summary, the prevalences of HBV and HCV that we report are lower than those docu-
mented previously. A significant number of the women with HBV were foreign born and/or
had a maternal family history of infection. Among those with HCV, many had a history of
IVDA, which probably influenced the fact that these women were less likely to complete follow
up and less likely to breastfeed their children. Over half of the women with HBV had viraemia,
and therefore were potential transmitters of the infection to the neonate. Therefore, the provi-
sion of appropriate immunoprophylaxis (including immunoglobulin therapy and vaccination)
is important in neonates born to HBV+ve mothers. However, among the women with HCV,
despite the presence of viraemia and coinfection with HIV, there was no transmission to the
children.
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5. Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, et al. Current preva-
lence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant
women in the EU/EEA: a systematic review. Epidemiol Infect 2017; 145(14):2873–85. https://doi.org/
10.1017/S0950268817001947 PMID: 28891457
6. Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C
en el Sistema Nacional de Salud. [Internet] Madrid: Ministerio de Sanidad, Servicios Sociales e Igual-
dad; 2015. Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/
plan_estrategico_hepatitis_C.pdf.
7. Cuadrado A, Perello C, Llerena S, Escudero-Garcı́a D, Gómez M, Estébanez A, et al. Design and cost
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